While the big four analgesic manufacturers — Bayer, Pfizer, McNeil and Novartis — command the lion’s share of retail ad support behind their mega analgesic brands, Prestige Brands and BedRock Brands are making headway promoting their niche pain relieving products.
There was a $1.1 billion gain in OTC sales between 2013 and 2014, according to data culled from IRI, some $500 million of which can be attributed to an increase in sales across all cough-cold/allergy/sinus products and an approximate $300 million to a rise in digestive sales.
In a meeting with nearly two dozen leaders representing consumers, insurers, providers and business leaders, Health and Human Services Secretary Sylvia Burwell on Jan. 26 announced measurable goals and a timeline to move the Medicare program, and the healthcare system at large, toward paying providers based on the quality of care they give patients.
Miraculins in January announced that it will be commencing a pilot program with Lovell Drugs and Pear Healthcare Solutions that will see the placement of the first stand-alone Scout DS diabetes screening kiosks in Lovell’s retail pharmacy locations in Ontario beginning in February.
Drug Store News has partnered with Competitive Promotion Report and IRI to create a series of exclusive reports. This edition explores cold/allergy/sinus products in both the liquid/powder and tablets/packets segments.